BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) on Tuesday agreed to acquire Astria Therapeutics, Inc. ( NASDAQ:ATXS ) for a mix of cash and stock. The deal represents an implied value of $13 per Astria share, and approximately $700 million in enterprise value.

ATXS

BioCryst制药

<p>BioCryst Pharmaceuticals, Inc.（纳斯达克代码：BCRX）周二同意以现金和股票的组合收购 Astria Therapeutics, Inc.（纳斯达克代码：ATXS）。该交易对 Astria 每股的隐含价值为 13 美元，企业价值约为 7 亿美元</p>

为什么 BioCryst 制药的股票今天下跌？